Webinar: Santhera Pharmaceuticals Duchenne Drug Development Update (March 24, 2021)
by: Parent Project Muscular Dystrophy
Santhera Pharmaceuticals joined Parent Project Muscular Dystrophy (PPMD) for a webinar on March 24, 2021 to provide an update to the community about the investigational therapy vamorolone, the use of steroids to treat Duchenne muscular dystrophy, clinical trials for vamorolone, and development timelines.